Parameters predicting COVID-19-induced myocardial injury and mortality.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Nov 2020
Historique:
received: 20 08 2020
revised: 01 09 2020
accepted: 03 09 2020
pubmed: 13 9 2020
medline: 11 11 2020
entrez: 12 9 2020
Statut: ppublish

Résumé

Clinical manifestations of COVID-19 affect many organs, including the heart. Cardiovascular disease is a dominant comorbidity and prognostic factors predicting risk for critical courses are highly needed. Moreover, immunomechanisms underlying COVID-induced myocardial damage are poorly understood. To elucidate prognostic markers to identify patients at risk. Only patients with pericardial effusion (PE) developed a severe disease course, and those who died could be identified by a high CD8/Treg/monocyte ratio. Ten out of 19 COVID-19 patients presented with PE, 7 (78%) of these had elevated APACHE-II mortality risk-score, requiring mechanical ventilation. At admission, PE patients showed signs of systemic and cardiac inflammation in NMR and impaired cardiac function as detected by transthoracic echocardiography (TTE), whereas parameters of myocardial injury e.g. high sensitive troponin-t (hs-TnT) were not yet increased. During the course of disease, hs-TnT rose in 8 of the PE-patients above 16 ng/l, 7 had to undergo ventilatory therapy and 4 of them died. FACS at admission showed in PE patients elevated frequencies of CD3 PE predicts cardiac injury in COVID-19 patients. Therefore, TTE should be performed at admission. Immunological parameters for dysfunctional antiviral immunity, such as the CD8/Treg/monocyte ratio used here, supports risk assessment by predicting poor prognosis.

Identifiants

pubmed: 32918975
pii: S0024-3205(20)31153-X
doi: 10.1016/j.lfs.2020.118400
pmc: PMC7480277
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118400

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Références

Eur Heart J. 2020 Jun 7;41(22):2070-2079
pubmed: 32391877
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Circ Cardiovasc Imaging. 2020 May;13(5):e010897
pubmed: 32397816
Life Sci. 2020 Sep 15;257:118058
pubmed: 32653518
Hum Immunol. 2000 Jan;61(1):74-81
pubmed: 10658980
Blood Cells Mol Dis. 2020 Jul;83:102437
pubmed: 32325421
Lancet. 2020 May 9;395(10235):1516
pubmed: 32334650
Life Sci. 2020 Jul 15;253:117723
pubmed: 32360126
Lancet Respir Med. 2020 May;8(5):e27
pubmed: 32203708
JACC Basic Transl Sci. 2020 Apr 10;5(5):537-542
pubmed: 32292847
Circulation. 2020 Sep 15;142(11):1123-1125
pubmed: 32689809
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273
pubmed: 32730619
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555

Auteurs

G D Duerr (GD)

Department of Cardiovascular Surgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

A Heine (A)

Department of Internal Medicine III for Hematology, Oncology, Rheumatology and Immune-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

M Hamiko (M)

Department of Cardiovascular Surgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

S Zimmer (S)

Department of Internal Medicine II - Cardiology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

J A Luetkens (JA)

Department of Radiology, Quantitative Imaging Lab Bonn (QILaB), University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

J Nattermann (J)

Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

G Rieke (G)

Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

A Isaak (A)

Department of Radiology, Quantitative Imaging Lab Bonn (QILaB), University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

J Jehle (J)

Department of Internal Medicine II - Cardiology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

S A E Held (SAE)

Department of Internal Medicine III for Hematology, Oncology, Rheumatology and Immune-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

J C Wasmuth (JC)

Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

M Wittmann (M)

Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

C P Strassburg (CP)

Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

P Brossart (P)

Department of Internal Medicine III for Hematology, Oncology, Rheumatology and Immune-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

M Coburn (M)

Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

H Treede (H)

Department of Cardiovascular Surgery, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

G Nickenig (G)

Department of Internal Medicine II - Cardiology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

C Kurts (C)

Institute for Experimental Immunology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany. Electronic address: ckurts@uni-bonn.de.

M Velten (M)

Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany. Electronic address: markus.velten@ukbonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH